Susquehanna International Group
PDLI

Susquehanna International Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Susquehanna International Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-86,100
Closed -$271K – 12172
2020
Q3 		$271K Buy
86,100
+4,200
+5% +$13.4K ﹤0.01% 8921
2020
Q2 		$238K Buy
81,900
+600
+0.7% +$1.9K ﹤0.01% 8741
2020
Q1 		$229K Sell
81,300
-41,600
-34% -$134K ﹤0.01% 8461
2019
Q4 		$399K Buy
122,900
+99,300
+421% +$288K ﹤0.01% 7435
2019
Q3 		$51K Sell
23,600
-29,400
-55% -$78.6K ﹤0.01% 9776
2019
Q2 		$166K Buy
53,000
+2,400
+5% +$7.79K ﹤0.01% 9289
2019
Q1 		$188K Buy
50,600
+36,300
+254% +$123K ﹤0.01% 7916
2018
Q4 		$41K Sell
14,300
-82,800
-85% -$227K ﹤0.01% 8548
2018
Q3 		$255K Buy
+97,100
New +$238K ﹤0.01% 7789
2018
Q1 		– Sell
-21,200
Closed -$58K – 10885
2017
Q4 		$58K Sell
21,200
-60,100
-74% -$185K ﹤0.01% 8878
2017
Q3 		$276K Sell
81,300
-31,900
-28% -$88.7K ﹤0.01% 7538
2017
Q2 		$280K Sell
113,200
-5,800
-5% -$13.3K ﹤0.01% 7711
2017
Q1 		$270K Buy
119,000
+90,400
+316% +$200K ﹤0.01% 7515
2016
Q4 		$61K Sell
28,600
-191,000
-87% -$533K ﹤0.01% 9242
2016
Q3 		$736K Buy
219,600
+45,700
+26% +$145K ﹤0.01% 5371
2016
Q2 		$546K Sell
173,900
-112,100
-39% -$374K ﹤0.01% 5978
2016
Q1 		$952K Buy
286,000
+245,400
+604% +$765K ﹤0.01% 5187
2015
Q4 		$144K Buy
40,600
+26,900
+196% +$113K ﹤0.01% 8676
2015
Q3 		$69K Sell
13,700
-52,600
-79% -$301K ﹤0.01% 9289
2015
Q2 		$426K Buy
66,300
+8,700
+15% +$58.3K ﹤0.01% 7930
2015
Q1 		$405K Sell
57,600
-51,100
-47% -$370K ﹤0.01% 7475
2014
Q4 		$838K Sell
108,700
-41,800
-28% -$331K ﹤0.01% 6207
2014
Q3 		$1.12M Sell
150,500
-164,700
-52% -$1.53M ﹤0.01% 5714
2014
Q2 		$3.05M Buy
315,200
+252,400
+402% +$2.25M ﹤0.01% 3894
2014
Q1 		$522K Buy
62,800
+49,300
+365% +$423K ﹤0.01% 6666
2013
Q4 		$114K Sell
13,500
-219,200
-94% -$1.85M ﹤0.01% 8581
2013
Q3 		$1.85M Buy
232,700
+153,500
+194% +$1.23M ﹤0.01% 4214
2013
Q2 		$612K Buy
+79,200
New +$618K ﹤0.01% 5746

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.46% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Susquehanna International Group's PDLI Position: Q4 2020 in Review

Susquehanna International Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 50,978 shares — an estimated $160K sold.

Susquehanna International Group first reported a position in PDLI in Q3 2013 and held it in 24 quarters. The position peaked at $6.86M in Q4 2013. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Susquehanna International Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Susquehanna International Group sold 50,978 PDL BioPharma, Inc. shares in Q4 2020, an estimated $160K.
  • Susquehanna International Group first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 24 quarters.
  • Susquehanna International Group's PDL BioPharma, Inc. position peaked at $6.86M in Q4 2013.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.